Orgenesis Inc. (ORGS)’s Financial Results Comparing With SELLAS Life Sciences Group Inc. (NASDAQ:SLS)

We will be contrasting the differences between Orgenesis Inc. (NASDAQ:ORGS) and SELLAS Life Sciences Group Inc. (NASDAQ:SLS) as far as dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Orgenesis Inc. 3 0.00 12.77M -1.42 0.00
SELLAS Life Sciences Group Inc. 6 0.00 4.86M -2.63 0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 hightlights the return on assets, return on equity and net margins of the two companies.

Net Margins Return on Equity Return on Assets
Orgenesis Inc. 382,438,381.60% -80.3% -30.4%
SELLAS Life Sciences Group Inc. 82,681,184.08% -600.2% -141.8%

Risk & Volatility

A beta of 1.26 shows that Orgenesis Inc. is 26.00% more volatile than Standard and Poor’s 500. Competitively, SELLAS Life Sciences Group Inc.’s beta is 1.3 which is 30.00% more volatile than Standard and Poor’s 500.

Liquidity

The Current Ratio and a Quick Ratio of Orgenesis Inc. are 1.1 and 1. Competitively, SELLAS Life Sciences Group Inc. has 0.6 and 0.6 for Current and Quick Ratio. Orgenesis Inc.’s better ability to pay short and long-term obligations than SELLAS Life Sciences Group Inc.

Analyst Recommendations

In next table is given Orgenesis Inc. and SELLAS Life Sciences Group Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Orgenesis Inc. 0 0 1 3.00
SELLAS Life Sciences Group Inc. 0 0 1 3.00

Orgenesis Inc.’s consensus target price is $9, while its potential upside is 226.09%. Meanwhile, SELLAS Life Sciences Group Inc.’s consensus target price is $12, while its potential upside is 164.90%. The data provided earlier shows that Orgenesis Inc. appears more favorable than SELLAS Life Sciences Group Inc., based on analyst belief.

Insider and Institutional Ownership

Orgenesis Inc. and SELLAS Life Sciences Group Inc. has shares owned by institutional investors as follows: 4.2% and 11.8%. 26.45% are Orgenesis Inc.’s share owned by insiders. Comparatively, 2.04% are SELLAS Life Sciences Group Inc.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Orgenesis Inc. 0.65% 9.65% -0.85% 6.15% -29.39% -0.43%
SELLAS Life Sciences Group Inc. 34.6% 47.83% -82.42% -88.36% -84.82% -86.18%

For the past year Orgenesis Inc. has stronger performance than SELLAS Life Sciences Group Inc.

Summary

On 9 of the 10 factors Orgenesis Inc. beats SELLAS Life Sciences Group Inc.

Orgenesis Inc., a biopharmaceutical company, develops trans-differentiation technologies in the field of cell therapy and regenerative medicine. The company's Contract Development and Manufacturing Organization segment specializes in cell therapy development for advanced medicinal products. This segment provides process and assay development services; and GMP contract manufacturing services. Its Cellular Therapy Business segment develops cell trans-differentiation technology induce shift in the developmental fate of cells from the liver and differentiating them into pancreatic beta cell-like insulin-producing cells for patients with diabetes. Orgenesis Inc. has a collaboration agreement with Biosequel LLC to carry out clinical trials and market its products in Russia, Belarus, and Kazakhstan. The company was formerly known as Business Outsourcing Services, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was founded in 2008 and is based in Germantown, Maryland.

SELLAS Life Sciences Group, Inc., a development-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications. The company's lead product candidate is galinpepimut-S, a cancer immunotherapeutic agent for the treatment of hematologic cancers and solid tumor indications, including acute myeloid leukemia, malignant pleural mesothelioma, multiple myeloma, ovarian cancer, immune combo, and chronic myelogenous leukemia. It also develops NEUVAX, which is in Phase II clinical trial for the treatment of breast cancer; and Anagrelide controlled release, which has completed various clinical trials for the treatment of thrombocythemia. The company has collaboration and license agreements with Memorial Sloan Kettering Cancer Center, Advaxis Immunotherapies, Merck & Co., Inc., National Cancer Institute, and the University of Texas M.D. Anderson Cancer Center. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.